Title | Audit of wet AMD patients treated with IV Ranibizumab over 6-12 months |
Abstract Nr. | 3028 |
Purpose | The “Treat and Extend” regimen (TER) was introduced to place the issue of monthly follow-ups, as a new and better approach for individualized patient care. Our study attempts to assess the change of the VA when using the TER. |
Methods | Between March 2013 and June 2016, 27 patients with neovascular AMD at Western Eye Hospital in London were included in the retrospective study. The inclusion criterion was: exudative AMD treated with Rnibizumab and with a minimal follow up of six months. We excluded patients who had treatment with other anti-VEGF, patients on PRN protocol were excluded from the study as well. Best-corrected visual acuity was collected at each visit and converted into logMAR unit, and CRT was recorded for each visit in which an OCT was used. |
Results | Twenty seven patients naïve exudatine AMD patients met the inclusion criteria and were recruited in this study Among the treated eyes included in this analysis, 41% experienced a significant VA gain of 15 ETDRS letters or more, 7% had a significant VA loss of 15 ETDRS letters or more and 52% obtained VA stabilization. |
Conclusion | Among the treated eyes included in this analysis, 41% experienced a significant VA gain of 15 ETDRS letters or more, 7% had a significant VA loss of 15 ETDRS letters or more and 52% obtained VA stabilization. |
Conflict of interest | Yes |
Details of conflicting interests | To discuss the effecacy of Ranbizumab Treat & Extend in treating patients with Wet AMD |
Last name | HAMOUD |
Initials | A |
Department | Medical Retina, Western Eye Hospital |
City | London |
Last name | Younis |
Initials | S |
Department | Medical Retina, Western Eye Hospital |
City | London |